- Home
- INTR vs HRMY Comparison
INTR vs HRMY Comparison
Compare INTR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- HRMY
- Stock Information
- Founded
- INTR 1994
- HRMY 2017
- Country
- INTR Brazil
- HRMY United States
- Employees
- INTR N/A
- HRMY N/A
- Industry
- INTR
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- INTR
- HRMY Health Care
- Exchange
- INTR Nasdaq
- HRMY Nasdaq
- Market Cap
- INTR 3.3B
- HRMY 2.0B
- IPO Year
- INTR N/A
- HRMY 2020
- Fundamental
- Price
- INTR $7.07
- HRMY $32.16
- Analyst Decision
- INTR Hold
- HRMY Strong Buy
- Analyst Count
- INTR 2
- HRMY 9
- Target Price
- INTR $5.55
- HRMY $54.22
- AVG Volume (30 Days)
- INTR 2.1M
- HRMY 609.1K
- Earning Date
- INTR 08-06-2025
- HRMY 08-05-2025
- Dividend Yield
- INTR 1.73%
- HRMY N/A
- EPS Growth
- INTR 97.58
- HRMY 13.13
- EPS
- INTR 0.40
- HRMY 2.62
- Revenue
- INTR $860,720,325.00
- HRMY $744,852,000.00
- Revenue This Year
- INTR $80.32
- HRMY $20.10
- Revenue Next Year
- INTR $17.51
- HRMY $18.01
- P/E Ratio
- INTR $17.68
- HRMY $12.27
- Revenue Growth
- INTR 39.90
- HRMY 20.62
- 52 Week Low
- INTR $3.88
- HRMY $26.47
- 52 Week High
- INTR $7.84
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- INTR 47.01
- HRMY 43.25
- Support Level
- INTR $6.86
- HRMY $31.70
- Resistance Level
- INTR $7.48
- HRMY $33.69
- Average True Range (ATR)
- INTR 0.21
- HRMY 0.89
- MACD
- INTR -0.07
- HRMY -0.10
- Stochastic Oscillator
- INTR 20.56
- HRMY 37.30
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.